AAV & Ex Vivo Gene Lentiviral Therapy
Douglas Sanders, Ph.D., VP Head of Translational Medicine at AVROBIO provides detailed examples of the diseases that are a better fit for AAV or ex vivo lentiviral gene therapy and why.
VIEW THE VIRTUAL EVENT! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online X
Subscribe to Bioprocess Online